The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Metabolism and Bioenergetics in the Right Ventricle and Pulmonary Vasculature in Pulmonary Hypertension
Open accessAbstract
Pulmonary arterial hypertension (PAH) is a syndrome in which pulmonary vascular cross sectional area and compliance are reduced by vasoconstriction, vascular remodeling, and inflammation. Vascular remodeling results in part from increased proliferation and impaired apoptosis of vascular cells. The resulting increase in afterload promotes right ventricular hypertrophy (RVH) and RV failure. Recently identified mitochondrial‐metabolic abnormalities in PAH, notably pyruvate dehydrogenase kinase‐mediated inhibition of pyruvate dehydrogenase (PDH), result in aerobic glycolysis in both the lung vasculature and RV. This glycolytic shift has diagnostic importance since it is detectable early in experimental PAH by increased lung and RV uptake of 18 F‐fluorodeoxyglucose on positron emission tomography. The metabolic shift also has pathophysiologic and therapeutic relevance. In RV myocytes, the glycolytic switch reduces contractility while in the vasculature it renders cells hyperproliferative and apoptosis‐resistant. Reactivation of PDH can be achieved directly by PDK inhibition (using dichloroacetate), or indirectly via activating the Randle cycle, using inhibitors of fatty acid oxidation (FAO), trimetazidine and ranolazine. In experimental PAH and RVH, PDK inhibition increases glucose oxidation, enhances RV function, regresses pulmonary vascular disease by reducing proliferation and enhancing apoptosis, and restores cardiac repolarization. FAO inhibition increases RV glucose oxidation and RV function in experimental RVH. The trigger for metabolic remodeling in the RV and lung differ. In the RV, metabolic remodeling is likely triggered by ischemia (due to microvascular rarefaction and/or reduced coronary perfusion pressure). In the vasculature, metabolic changes result from redox‐mediated activation of transcription factors, including hypoxia‐inducible factor 1α, as a consequence of epigenetic silencing of SOD2 and/or changes in mitochondrial fission/fusion. Randomized controlled trials are required to assess whether the benefits of enhancing glucose oxidation are realized in patients with PAH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Randle, P. J., Garland, P. B., Hales, C. N., & Newsholme, E. A. (1963) · The Lancet · doi:10.1016/s0140-6736(63)91500-9 · Cited by 5,093
Updated clinical classification of pulmonary hypertension
Simonneau, G., Gatzoulis, M. A., Adatia, I., Celermajer, D., Denton, C., Ghofrani, A., Gomez Sanchez, M. A., Krishna Kumar, R., Landzberg, M., Machado, R. F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.029 · Cited by 4,191
Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1
Manalo, D. J., Rowan, A., Lavoie, T., Natarajan, L., Kelly, B. D., Ye, S. Q., Garcia, J. G. N., & Semenza, G. L. (2005) · Blood · doi:10.1182/blood-2004-07-2958 · Cited by 1,154
van de Veerdonk, M. C., Kind, T., Marcus, J. T., Mauritz, G.-J., Heymans, M. W., Bogaard, H.-J., Boonstra, A., Marques, K. M. J., Westerhof, N., & Vonk-Noordegraaf, A. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.068 · Cited by 846
Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts
McCormack, J. G., Barr, R. L., Wolff, A. A., & Lopaschuk, G. D. (1996) · Circulation · doi:10.1161/01.cir.93.1.135 · Cited by 291
Efficacy of Ranolazine in Patients With Chronic Angina
Wilson, S. R., Scirica, B. M., Braunwald, E., Murphy, S. A., Karwatowska-Prokopczuk, E., Buros, J. L., Chaitman, B. R., & Morrow, D. A. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.01.037 · Cited by 198 · cited 2×
“[34] Ranolazine is approved for refractory angina in the USA.”
Background
Cited by
Vonk Noordegraaf, A., Chin, K. M., Haddad, F., Hassoun, P. M., Hemnes, A. R., Hopkins, S. R., Kawut, S. M., Langleben, D., Lumens, J., & Naeije, R. (2019) · European Respiratory Journal · doi:10.1183/13993003.01900-2018 · Cited by 569
Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension
Bertero, T., Oldham, W. M., Cottrill, K. A., Pisano, S., Vanderpool, R. R., Yu, Q., Zhao, J., Tai, Y., Tang, Y., Zhang, Y.-Y., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86387 · Cited by 439
Lahm, T., Douglas, I. S., Archer, S. L., Bogaard, H. J., Chesler, N. C., Haddad, F., Hemnes, A. R., Kawut, S. M., Kline, J. A., Kolb, T. M., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201806-1160st · Cited by 343
Self-citationNew insights into the role of mitochondria in cardiac microvascular ischemia/reperfusion injury
Wang, J., Toan, S., & Zhou, H. (2020) · Angiogenesis · doi:10.1007/s10456-020-09720-2 · Cited by 311
Bujak, R., Daghir-Wojtkowiak, E., Kaliszan, R., & Markuszewski, M. J. (2016) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2016.00035 · Cited by 81
Metadata
- Authors
- Archer, S. L., Fang, Y., Ryan, J. J., & Piao, L.
- Venue
- Pulmonary Circulation
- Publisher
- Wiley
- Published
- 2013-01
- Volume
- 3
- Issue
- 1
- Pages
- 144-152
- ISSN
- 2045-8932 (ISSN-L)
- 2045-8940
- OpenAlex
- W2005097808
- Cited by
- 181
- References
- 6
- FWCI
- 14.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabolism and Bioenergetics in the Right Ventricle and Pulmonary Vasculature in Pulmonary Hypertension. https://app.cochat.ai/papers/10.4103/2045-8932.109960
- The paper
- Archer, S. L., Fang, Y., Ryan, J. J., & Piao, L. (2013). Metabolism and Bioenergetics in the Right Ventricle and Pulmonary Vasculature in Pulmonary Hypertension. Pulmonary Circulation. https://doi.org/10.4103/2045-8932.109960
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.